ArticleJournal of fish diseases2026
White Spot Syndrome Virus Envelope Protein VP53B Functions as a Trypsin Inhibitor and Interacts With Hemocyanin.
Article in Journal of fish diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
White spot syndrome virus (WSSV) remains a persistent and significant threat to the global shrimp aquaculture industry. However, its pathogenic mechanisms remain incompletely understood, and no effective intervention strategies are currently available. In this study, we investigated the functional role of VP53B, an envelope structural protein of WSSV, using a combination of infection bioassays, protein structure prediction, protease inhibition assays and protein binding analyses. Our results demonstrate that VP53B is a critical determinant of per os (oral) infection in shrimp, including Procambarus clarkii (crayfish) and Litopenaeus vannamei (whiteleg shrimp). Functionally, VP53B acts as a trypsin inhibitor and interacts with host hemocyanin. We propose that through modulation of shrimp trypsin and hemocyanin, VP53B disrupts the prophenoloxidase-activating system, a key innate immune pathway, thereby facilitating successful WSSV infection. This study provides new insights into the molecular mechanisms underlying WSSV oral infectivity and highlights VP53B as a potential target for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.